Our clinical trials are enrolling patients during the pandemic More Here
Read the November/December issue of News from ECOG-ACRIN
Read our Advocacy Blog on screening and surveillance
Read the Q3 issue of the TMIST Study Updates Newsletter
Question about COVID19? Send an email
Video: Roisin M. Connolly, MD, lead investigator for study E2112, discusses the trial results. Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes. December 14, 2020. Medicine Matters Oncology
The new RSClinTM tool integrates clinical-pathological and genomic risk to guide adjuvant chemotherapy in node-negative breast cancer and provides more individualized information than clinical-pathological or genomic data alone, according to Joseph Sparano, MD, and colleagues. December 11, 2020. Journal of Clinical Oncology
Better Together: Clinical and Genomic Data to Inform Shared Decision Making. An editorial accompanying RSClinTM validation analysis. December 11, 2020. Journal of Clinical Oncology
First-ever phase III clinical trial opens for patients with advanced, inoperable anal cancer. November 16, 2020. Read Press Release
View our YouTube channel for these and other videos:
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD